Report / Trial registry metadata
Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation
This study concerns Coronary Artery Disease (CAD), Menopause, Hormones. Its registered status is recruiting. The planned measures below describe the study design, not demonstrated treatment effects.
What is being studied?
- Conditions
- Coronary Artery Disease (CAD), Menopause, Hormones
- Study type
- Interventional
- Purpose
- Prevention
- Phase
- NA
How is the study designed?
- Enrollment
- 80 (estimated)
- Group design
- Parallel
- Allocation
- Randomized
- Masking
- Triple
- Minimum age
- 45 Years
- Maximum age
- 70 Years
- Eligibility sex
- Female
Which interventions are listed?
- Dietary supplement: Trans-resveratrol, 1000 mg daily for 90 days
- Other: Placebo
What will the study measure?
- 1. Sirtuin-1 and sirtuin-3 Assessment window: 90 days
- Estradiol Assessment window: 90 days
- Estrone Assessment window: 90 days
- SHBG Assessment window: 90 days
What can this record establish?
These are registered plans and status information. Enrollment marked estimated is a target, not a verified count of participants already studied. The measures listed do not establish that an intervention succeeded. Eligibility criteria and recruitment status must be checked against the full study record before considering participation.
- Kind
- Trial registry metadata
- Identifier
- NCT07865377
- Status
- RECRUITING